013 reflect the evolution of our significant investment in clinical science over the last several years, and will help guide physicians in making important patient care decisions. With the approval of our iFR modality in Europe
and the U.S. launch of the new Verrata™ Pressure Guide Wire, our goal is to further simplify workflows so that these advanced technologies become a faster, simpler and more routine part of everyday practice and can benefit more patients."
Volcano will display its products and technologies at Booth 1104, Exhibit H., including three new launches:
- Verrata™ Pressure Guide Wire,
- Crux® Vena Cava Filter, and
- iFR® modality (CE Mark countries and Japan only).
The company will also host a Breakfast Symposium that will showcase data from ADVISE II and the ADAPT-DES IVUS analysis, and review the upcoming SYNTAX II study. Specific details follow.
Key Presentations in the Scientific Program
Tuesday, October 29, 1:15 p.m.
Does IVUS Reduce Stent Thrombosis with DES? Two-Year Results from the Prospective, Multicenter ADAPT-DES Study
Presented by Akiko Maehara, M.D.
Moscone West, 2nd Floor, Room 2010
Wednesday, October 30, 1:54 - 2:06 p.m.
A Prospective, Registry Evaluation of iFR vs. FFR: ADVISE II*
Presented by Javier Escaned, M.D., Ph.D.
Moscone North, Lower Level, Hall D, Coronary Theater
*First Report Investigation
Volcano-Sponsored Breakfast Symposium
Putting Appropriateness Within Reach: New Global Clinical Data and Workflows
Thursday, October 31
The Moscone Center, Moscone North, Lower Level, Room 132
7:00 a.m.Page: 1 2 3 4 Related medicine technology :1
State of the Union on Global PCI Guidelines Today and Where to Expand in the Fu
. Volcano Corporation Presentation At JMP Securities Conference To Be Webcast2
. Volcano to Highlight its Leadership in Precision Guided Therapy at EuroPCR 20123
. Volcano Corporation Presentation At Jefferies Conference To Be Webcast4
. Volcano Corporation Presentation at Wells Fargo Conference to be Webcast5
. Volcano Corporation Schedules Second Quarter Conference Call, Webcast6
. Volcano Corporation Reports 13 Percent Growth In Second Quarter Revenues; FFR Disposable Revenues Increase 38 Percent7
. Volcano Corporation Presentation At Canaccord Genuity Conference To Be Webcast8
. FAME 2 Published in the New England Journal of Medicine, Volcano participates in the $84M NIH-Sponsored ISCHEMIA Trial9
. Volcano Corporation Presentation At Stifel Nicolaus Conference To Be Webcast10
. Volcano Announces Previous St. Jude Medical Products Infringe Volcano Patent and Jury Verdicts in Patent Trials with St. Jude Medical11
. Volcano Corporation Schedules Third Quarter Conference Call, Webcast